Founded in 1927, Littelfuse is a diversified industrial technology manufacturing company empowering a more sustainable, connected, and safer world. Across more than 20 countries, and with approximately 16,000 global associates, we partner with customers to design and deliver innovative, reliable application solutions. Littelfuse offers an extensive technology portfolio— switches, sensors, TVS diodes, diode arrays, fuses, semiconductors, polymers, ceramics, relays, and more. Serving over 100,000 end customers, our products are found in a variety of health care, electronics, and mobile end markets— everywhere, every day. Littelfuse offers solutions for various health care applications, including auto-injectors or drug delivery pens, Continuous Glucose Monitors (CGM), insulin pumps, and wearable injectors. Discover how Littelfuse components and system modeling can optimize your designs for cost-effective, high-performance medical devices. Visit us at Booth #611 to stay ahead in medical innovation.

Intrepid Labs accelerates drug formulation using AI, automation, and deep pharmaceutical expertise. Our proprietary platforms combine automated experimentation and machine learning to rapidly design, optimize, and characterize drug products. We partner with pharma and biotech to solve complex formulation challenges. Founded in 2023, Intrepid is building a data-driven, scalable, and patient-focused future for drug development.

For more information, please visit https://www.trutechnologies.io/ 

Samyang is a multinational conglomerate founded in South Korea in 1924, operating across diverse sectors including Biopharmaceuticals, Food, Chemicals, Packaging, and Cosmetics. Over the past decades, Samyang has built a strong foundation in drug delivery systems, leveraging its expertise in biodegradable polymers and polymeric micelle formulation technology. This dedication has led to the successful commercialization of modified anti-cancer generics and medical devices, earning global recognition for quality and safety. Currently, our primary focus is on the development of SENS™ (Selectivity Enabling Nano Shell) — a novel drug delivery platform designed for tissue-selective delivery of nucleic acid therapeutics. SENS™ is uniquely composed of biodegradable polymers and newly discovered cationic lipids. By adjusting composition and fine-tuning formulation processes, SENS™ enables targeted delivery of mRNA to specific tissues (e.g., spleen, lung, muscle, liver) while offering superior safety profiles that support repeat dosing. One of our key innovations, NanoReady, is a proprietary, ready-to-use SENS™ formulation. This pre-made nanoparticle system can be easily combined with mRNA immediately before administration, streamlining process development, reducing time-to-patient, and enabling personalized cancer vaccines. Through active collaboration with global partners, we are expanding our SENS™ platform across a range of mRNA-based therapeutics—including prophylactic and therapeutic cancer vaccines, protein replacement therapies, gene editing medicines, and more. We are actively seeking strategic partnerships with drug developers aiming to bring RNA therapies into the clinic. By combining their therapeutic innovations with our validated delivery modalities, we can enable safe and selective targeting, maximize clinical impact, and deliver novel therapies to patients.